HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Bronchopulmonary dysplasia of newborn — Clinical Guidelines

Overview

Bronchopulmonary dysplasia (BPD) is a chronic lung disorder primarily affecting preterm infants who require prolonged mechanical ventilation and oxygen support, leading to significant respiratory morbidity, prolonged hospitalization, and potential long-term pulmonary complications 1 2.

Diagnosis

Key Diagnostic Criteria: Prolonged mechanical ventilation, supplemental oxygen requirement beyond 28 days of life, characteristic radiographic findings (hyperinflation, air trapping, and cystic changes), and clinical signs of respiratory distress 1 2.

Recommended Tests: Chest X-rays, pulmonary function tests (when developmentally appropriate), blood gas analysis 1 2.

Grading: Clinical severity often graded based on oxygen requirements and respiratory support needs, though standardized grading systems vary 1 2.

Management

First-Line Treatments: Gradual reduction of oxygen and ventilator support, use of surfactant therapy 1 2.

Adjunctive Therapies: Vitamin D supplementation to potentially reduce BPD incidence (400 IU daily) 1 4.

Specific Drug Classes: Vitamin A supplementation shown to benefit high-risk infants (401-1000 g birth weight) 6.

Considerations: Management post-discharge involves careful weaning from supplemental oxygen and close monitoring by pediatric pulmonologists 10 13.

Special Populations

Premature Infants: Higher risk of BPD, especially those with lower gestational age 1 4.

Comorbidities: Socioeconomic barriers can impact decannulation outcomes in infants with BPD 3.

Key Recommendations

Vitamin D Supplementation: Administer 400 IU daily to preterm infants to potentially reduce the incidence of BPD (Evidence: Moderate) 1 4.

Targeted Vitamin A Therapy: Reserve vitamin A injections for high-risk infants (401-1000 g birth weight) to prevent BPD or reduce mortality (Evidence: Moderate) 6.

Careful Weaning Process: Implement structured outpatient strategies for weaning supplemental oxygen in premature infants post-discharge to manage BPD effectively (Evidence: Expert opinion) 10 13.

References

1 Rebele T, Hawes C, Johnson S, Newkirk M. Effect of vitamin D supplementation on incidence of bronchopulmonary dysplasia among preterm infants up to 36 weeks' gestational age. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2025. link 2 Wu S, Ryan RM, Auten RL. 2022 Year in review: Neonatal pulmonology. Pediatric pulmonology 2023. link 3 Lloyd AM, Behzadpour HK, Rana MS, Espinel AG. Factors associated with tracheostomy decannulation in infants with bronchopulmonary dysplasia. International journal of pediatric otorhinolaryngology 2023. link 4 Byun SY, Bae MH, Lee NR, Han YM, Park KH. Association between vitamin D deficiency at one month of age and bronchopulmonary dysplasia. Medicine 2021. link 5 Ge H, Liu W, Li H, Zhang M, Zhang M, Liu C et al.. The association of vitamin D and vitamin E levels at birth with bronchopulmonary dysplasia in preterm infants. Pediatric pulmonology 2021. link 6 Rysavy MA, Li L, Tyson JE, Jensen EA, Das A, Ambalavanan N et al.. Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial. The Journal of pediatrics 2021. link 7 Jang YE, Kim EH, Lee JH, Kim HS, Kim JT. Guidewire-assisted vs. direct radial arterial cannulation in neonates and infants: A randomised controlled trial. European journal of anaesthesiology 2019. link 8 Valeur KS, Hertel SA, Lundstrøm KE, Holst H. The Cumulative Daily Tolerance Levels of Potentially Toxic Excipients Ethanol and Propylene Glycol Are Commonly Exceeded in Neonates and Infants. Basic & clinical pharmacology & toxicology 2018. link 9 Lundeberg S, Stephanson N, Stiller CO, Eksborg S. Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates. Acta anaesthesiologica Scandinavica 2012. link 10 Palm K, Simoneau T, Sawicki G, Rhein L. Assessment of current strategies for weaning premature infants from supplemental oxygen in the outpatient setting. Advances in neonatal care : official journal of the National Association of Neonatal Nurses 2011. link 11 Guan CX, Cui YR, Zhang M, Bai HB, Khunkhun R, Fang X. Intracellular signaling molecules involved in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells. Peptides 2007. link 12 Buschbacher R. Outcomes and problems in pediatric pulmonary rehabilitation. American journal of physical medicine & rehabilitation 1995. link 13 Lynch M. Continuing education: bronchopulmonary dysplasia: management after discharge. Home healthcare nurse 1989. link 14 Perlman JM, Volpe JJ. Movement disorder of premature infants with severe bronchopulmonary dysplasia: a new syndrome. Pediatrics 1989. link 15 Hennequin Y, Pardou A, Detemmerman D, Vermeylen D, Muller F, Vandermoten G et al.. Partial bronchial stenosis following inadvertent right bronchial intubation in a neonate. Acta anaesthesiologica Belgica 1985. link

Bronchopulmonary dysplasia of newborn